The phase 3 clinical trial aims to evaluate the safety and efficacy of the investigational topical cream in a larger patient population. Leveraging the convincing results from phase 2 clinical studies, the trial will be conducted in a randomized, double-blind, placebo-controlled format, ensuring robust and reliable data collection and allowing for a comprehensive assessment of the potential benefits of MH004 Cream.

"We are excited to announce the commencement of the phase 3 clinical trial for our topical cream in mild to moderate atopic dermatitis." stated Guoqing Cao, Ph.D., Chief Executive Officer at Minghui Pharmaceutical. "The first patient enrollment marks a crucial moment in our journey to bring innovative treatments to those in need. Our team remains dedicated to rigorous research and development, and we are grateful to the patients, caregivers, and medical professionals who have participated in earlier stages, making this advancement possible."

Throughout the trial, Minghui Pharmaceutical is committed to upholding the highest standards of patient safety, ethical conduct, and scientific integrity. The company remains optimistic about the trial's progress and anticipates sharing the topline data of the phase 3 trial with the medical community and regulatory authorities in H2 2024, with the goal of providing a potential breakthrough treatment option for patients living with mild to moderate atopic dermatitis.